8-K: Alumis Inks $40 Million Deal with Kaken Pharmaceutical for ESK-001 Dermatology Rights in Japan

Alumis grants Kaken Pharmaceutical exclusive rights to develop and commercialize ESK-001 for dermatology in Japan, securing $40 million in upfront and near-term payments.

Summary

• Alumis Inc. has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for ESK-001 in Japan.
• Kaken gains exclusive rights to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with options to expand into rheumatological and gastrointestinal diseases.
• Alumis will receive $20 million upfront and $20 million towards global development costs through 2026.
• Alumis is eligible for up to $140 million in regulatory and commercial milestone payments and tiered royalties on net sales in Japan.
• Kaken will handle clinical development, regulatory approvals, and commercialization in Japan.
• Alumis retains rights to ESK-001 in all other indications and geographies.
• Alumis estimates its current cash position, combined with the Kaken payments, will fund its pipeline through the Phase 3 ONWARD program topline data readout.
• The reported cash position is preliminary and subject to change.
• The company is developing a once-daily modified release oral formulation of ESK-001 designed to replace the current immediate release oral formulation that is dosed twice daily.
• ESK-001 is also being evaluated in LUMUS, a Phase 2b clinical trial for the treatment of patients with systemic lupus erythematosus.

Sentiment

Score: 8

Explanation: The announcement is positive due to the significant upfront funding, potential milestone payments, and validation of Alumis' technology. The partnership with Kaken also provides access to the Japanese market and expertise in dermatology.

Positives

• The collaboration provides Alumis with significant upfront funding and potential future revenue through milestones and royalties.
• The agreement validates the commercial potential of ESK-001.
• Kaken's expertise in the Japanese market should accelerate the development and commercialization of ESK-001 in Japan.
• The deal extends Alumis' cash runway, allowing it to progress its pipeline through key milestones.
• Alumis retains rights to ESK-001 in all other geographies and indications outside of Kaken's option.

Negatives

• The preliminary cash position is subject to change and has not been audited.
• The success of ESK-001 in Japan is dependent on Kaken's ability to successfully develop and commercialize the product.
• Alumis is reliant on Kaken for clinical development, regulatory approvals and commercialization of ESK-001 in Japan.

Risks

• The forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• Alumis' ability to obtain regulatory approval and commercialize its clinical candidates is subject to risks and uncertainties.
• Alumis' ability to fund development activities and achieve development goals is subject to risks and uncertainties.
• Alumis' ability to protect its intellectual property is subject to risks and uncertainties.

Future Outlook

Alumis expects its current cash position, combined with payments from the Kaken agreement, to fund its pipeline through the topline data readout for the Phase 3 ONWARD program.

Management Comments

• Martin Babler, President and Chief Executive Officer of Alumis, stated that the partnership builds on positive Phase 2 clinical data and supports the objective of making ESK-001 widely accessible.
• Hiroyuki Horiuchi, President and Representative Director of Kaken, expressed strong belief in the potential of ESK-001 to address medical needs in dermatology and potentially rheumatological and gastrointestinal diseases.

Industry Context

This agreement highlights the increasing interest in TYK2 inhibitors for immune-mediated diseases and the value of regional partnerships for pharmaceutical companies to expand their reach.

Comparison to Industry Standards

• Other companies developing TYK2 inhibitors include Bristol Myers Squibb (Deucravacitinib) and Takeda.
• Deucravacitinib has already been approved for psoriasis, setting a high bar for efficacy and safety.
• The deal terms are comparable to other licensing agreements in the dermatology space, with upfront payments, milestone payments, and tiered royalties being standard components.
• The specific royalty rates and milestone amounts will depend on the stage of development and the perceived market potential of ESK-001.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential future revenue from the collaboration.
• Patients in Japan may gain access to a new treatment option for dermatology conditions.
• Employees of Alumis may benefit from the company's increased financial stability and growth prospects.

Next Steps

• Kaken will be responsible for clinical development, regulatory approvals, and commercialization of ESK-001 in Japan.
• Alumis will continue to advance its Phase 3 ONWARD program for ESK-001 in psoriasis.
• Alumis will continue to develop A-005, a clinical-stage, CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.
• Alumis will continue to leverage its precision data analytics platform to explore ESK-001s potential application in other immune-mediated conditions.

Key Dates

Keywords

ESK-001, Kaken Pharmaceutical, Alumis, Collaboration Agreement, Licensing Agreement, Dermatology, TYK2 inhibitor, Japan, Milestone Payments, Royalties